United Kingdom - English - VMD (Veterinary Medicines Directorate)

cross vetpharm group ltd - triclabendazole - oral suspension - anthelmintic flukicide - cattle, sheep

United Kingdom - English - VMD (Veterinary Medicines Directorate)

bimeda animal health limited - triclabendazole - oral suspension - anthelmintic flukicide - cattle, sheep

Ireland - English - HPRA (Health Products Regulatory Authority)

bimeda animal health limited - triclabendazole - oral suspension - 100 milligram(s)/millilitre - triclabendazole

Israel - English - Ministry of Health

novo nordisk ltd., israel - eptacog alfa (activated) - powder for solution for injection - eptacog alfa (activated) 1 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - novoseven ® rt is indicated for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups: •in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bethesda units (bu) •in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration •in patients with acquired haemophilia •in patients with congenital fvii deficiency •in patients with glanzmann’s thrombasthenia with past or present refractoriness to platelet transfusions, or where platelets are not readily available.severe postpartum haemorrhagenovoseven rt is indicated for the treatment of severe postpartum haemorrhage when uterotonics are insufficient to achieve haemostasis

Israel - English - Ministry of Health

novo nordisk ltd., israel - eptacog alfa (activated) - powder for solution for injection - eptacog alfa (activated) 2 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - novoseven ® rt is indicated for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups: •in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bethesda units (bu) •in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration •in patients with acquired haemophilia •in patients with congenital fvii deficiency •in patients with glanzmann’s thrombasthenia with past or present refractoriness to platelet transfusions, or where platelets are not readily available.severe postpartum haemorrhagenovoseven rt is indicated for the treatment of severe postpartum haemorrhage when uterotonics are insufficient to achieve haemostasis

Israel - English - Ministry of Health

novo nordisk ltd., israel - eptacog alfa (activated) - powder for solution for injection - eptacog alfa (activated) 5 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - novoseven ® rt is indicated for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups: •in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bethesda units (bu) •in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration •in patients with acquired haemophilia •in patients with congenital fvii deficiency •in patients with glanzmann’s thrombasthenia with past or present refractoriness to platelet transfusions, or where platelets are not readily available.severe postpartum haemorrhagenovoseven rt is indicated for the treatment of severe postpartum haemorrhage when uterotonics are insufficient to achieve haemostasis

New Zealand - English - Ministry for Primary Industries

schering-plough animal health limited - eimeria praecox (attenuated) hp; eimeria tenella (attenuated) hp; eimeria acervulina (attenuated) hp; eimeria maxima (attenuated) mfp; eimeria brunetti (attenuated) hp; eimeria mitis (attenuated) hp; eimeria necatrix (attenuated) hp; eimeria maxima (attenuated) cp - eimeria praecox (attenuated) hp 0 vaccine; eimeria tenella (attenuated) hp 0 vaccine; eimeria acervulina (attenuated) hp 0 vaccine; eimeria maxima (attenuated) mfp 0 vaccine; eimeria brunetti (attenuated) hp 0 vaccine; eimeria mitis (attenuated) hp 0 vaccine; eimeria necatrix (attenuated) hp 0 vaccine; eimeria maxima (attenuated) cp 0 vaccine - vaccine

New Zealand - English - Ministry for Primary Industries

schering-plough animal health limited - eimeria acervulina (attenuated) hp; eimeria maxima (attenuated) cp; eimeria maxima (attenuated) mfp; eimeria mitis (attenuated) hp; eimeria tenella (attenuated) hp - eimeria acervulina (attenuated) hp 0 vaccine; eimeria maxima (attenuated) cp 0 vaccine; eimeria maxima (attenuated) mfp 0 vaccine; eimeria mitis (attenuated) hp 0 vaccine; eimeria tenella (attenuated) hp 0 vaccine - vaccine

European Union - English - EMA (European Medicines Agency)

laboratoire francais du fractionnement et des biotechnologies - eptacog beta (activated) - hemophilia a; hemophilia b - antihemorrhagics - cevenfacta is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with high-responding inhibitors to coagulation factors viii or ix (i.e. ≥5 bethesda units (bu)); in patients with congenital haemophilia with low titre inhibitors (bu

European Union - English - EMA (European Medicines Agency)

novo nordisk a/s - eptacog alfa (activated) - hemophilia b; thrombasthenia; factor vii deficiency; hemophilia a - antihemorrhagics - novoseven is indicated for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bethesda units (bu);in patients with congenital haemophilia who are expected to have a high anamnestic response to factor-viii or factor-ix administration;in patients with acquired haemophilia;in patients with congenital factor-vii deficiency;in patients with glanzmann's thrombasthenia with antibodies to platelet glycoprotein (gp) iib-iiia and / or human leucocyte antigens (hla), and with past or present refractoriness to platelet transfusions.in patients with glanzmann’s thrombasthenia with past or present refractoriness to platelet transfusions, or where platelets are not readily available.